238 related articles for article (PubMed ID: 32501183)
21. The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients.
Reddy A; Vidal M; Stephen S; Baumgartner K; Dost S; Nguyen A; Heung Y; Kwan S; Wong A; Pangemanan I; Azhar A; Tayjasanant S; Rodriguez E; Waletich J; Lim KH; Wu J; Liu D; Williams J; Yennurajalingam S; Bruera E
J Pain Symptom Manage; 2017 Sep; 54(3):280-288. PubMed ID: 28711751
[TBL] [Abstract][Full Text] [Related]
22. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.
Donner B; Zenz M; Tryba M; Strumpf M
Pain; 1996 Mar; 64(3):527-534. PubMed ID: 8783318
[TBL] [Abstract][Full Text] [Related]
23. Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study.
Watanabe S; Pereira J; Hanson J; Bruera E
J Pain Symptom Manage; 1998 Nov; 16(5):323-6. PubMed ID: 9846027
[TBL] [Abstract][Full Text] [Related]
24. [Opioid rotation in pain therapy. Case report].
Kefalianakis F; Kugler M; van der Auwera R; Kugler G
Anaesthesist; 2002 Jan; 51(1):28-32. PubMed ID: 11963297
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.
Hoya Y; Okamoto T; Yanaga K
Support Care Cancer; 2010 Jun; 18(6):761-4. PubMed ID: 20354734
[TBL] [Abstract][Full Text] [Related]
26. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
[TBL] [Abstract][Full Text] [Related]
27. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study.
Lawlor P; Turner K; Hanson J; Bruera E
Pain; 1997 Aug; 72(1-2):79-85. PubMed ID: 9272790
[TBL] [Abstract][Full Text] [Related]
28. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.
Jeal W; Benfield P
Drugs; 1997 Jan; 53(1):109-38. PubMed ID: 9010652
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
30. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
[TBL] [Abstract][Full Text] [Related]
31. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.
Morita T; Takigawa C; Onishi H; Tajima T; Tani K; Matsubara T; Miyoshi I; Ikenaga M; Akechi T; Uchitomi Y;
J Pain Symptom Manage; 2005 Jul; 30(1):96-103. PubMed ID: 16043013
[TBL] [Abstract][Full Text] [Related]
32. Continuous fentanyl infusion: use in severe cancer pain.
Lenz KL; Dunlap DS
Ann Pharmacother; 1998 Mar; 32(3):316-9. PubMed ID: 9533063
[TBL] [Abstract][Full Text] [Related]
33. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F
Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107
[TBL] [Abstract][Full Text] [Related]
34. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
35. A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Koike K; Terui T; Nagasako T; Horiuchi I; Machino T; Kusakabe T; Hirayama Y; Mihara H; Yamakage M; Kato J; Nishisato T; Ishitani K
Support Care Cancer; 2016 Mar; 24(3):1053-9. PubMed ID: 26248654
[TBL] [Abstract][Full Text] [Related]
36. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Oosten AW; Abrantes JA; Jönsson S; de Bruijn P; Kuip EJ; Falcão A; van der Rijt CC; Mathijssen RH
Eur J Clin Pharmacol; 2016 Apr; 72(4):459-67. PubMed ID: 26762381
[TBL] [Abstract][Full Text] [Related]
37. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
38. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.
Muijsers RB; Wagstaff AJ
Drugs; 2001; 61(15):2289-307. PubMed ID: 11772140
[TBL] [Abstract][Full Text] [Related]
39. [Dose-finding for treatment with a transdermal fentanyl patch : Titration with oral transmucosal fentanyl citrate and morphine sulfate].
Mücke M; Conrad R; Marinova M; Cuhls H; Elsner F; Rolke R; Radbruch L
Schmerz; 2016 Dec; 30(6):560-567. PubMed ID: 27072143
[TBL] [Abstract][Full Text] [Related]
40. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain.
Moryl N; Santiago-Palma J; Kornick C; Derby S; Fischberg D; Payne R; Manfredi PL
Pain; 2002 Apr; 96(3):325-328. PubMed ID: 11973005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]